OSMOL THERAPEUTICS
Osmol Therapeutics develops treatment to prevent chemotherapy-induced peripheral neuropathy. The company was founded in 2016 and is headquartered in New Haven, Connecticut, United States.
OSMOL THERAPEUTICS
Industry:
Health Care Pharmaceutical Therapeutics
Founded:
2016-01-01
Address:
New Haven, Connecticut, United States
Country:
United States
Website Url:
http://www.osmoltherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
617-719-9406
Total Funding:
5.2 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail IPv6 Microsoft Azure DNS Cloudflare Hosting Cloudflare DNS CPanel SSL Oracle Cloud
Current Employees Featured
Investors List
Koax Investment Partners
Koax Investment Partners investment in Series A - Osmol Therapeutics
Official Site Inspections
http://www.osmoltherapeutics.com
- Host name: 198.185.159.144
- IP address: 198.185.159.144
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Osmol Therapeutics"
About Us — OSMOL Therapeutics
Osmol Therapeutics is a clinical stage company advancing a first-in-class preventative treatment for chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI), debilitating conditions …See details»
Osmol Therapeutics - Crunchbase Company Profile
Osmol Therapeutics develops treatment to prevent chemotherapy-induced peripheral neuropathy. The company was founded in 2016 and is headquartered in New Haven, Connecticut, United States.See details»
Osmol Therapeutics - LinkedIn
Osmol Therapeutics | 414 followers on LinkedIn. Addressing the urgent need of patients faced with the challenges of CIPN and CICI through the advancement of OSM-0205 | Osmol Therapeutics is ...See details»
Osmol Therapeutics - Org Chart, Teams, Culture & Jobs - The Org
View Osmol Therapeutics' up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Osmol Company Profile 2024: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for Osmol. Use the PitchBook Platform to explore the full profile.See details»
Leadership - Osmol Therapeutics
Bob Linke is a biopharma entrepreneur with a proven track record building and leading emerging companies through all phases of growth – from product development and clinical studies to successful commercialization, partnership …See details»
Osmol Therapeutics - Overview, News & Similar companies
May 15, 2024 Osmol Therapeutics contact info: Phone number: (203) 606-5600 Website: www.osmoltherapeutics.com What does Osmol Therapeutics do? Osmol Therapeutics is a …See details»
OSMOL THERAPEUTICS, INC. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for OSMOL THERAPEUTICS, INC. of New Haven, CT. Get the latest business insights from Dun & …See details»
Therapeutic Areas — OSMOL Therapeutics
Taxanes cross the blood-brain barrier causing damage to the central nervous system (CNS) leading to cognitive impairment. CICI impacts attention, concentration, and executive function domains, as well as increases …See details»
Osmol Therapeutics Announces Closing of Series A-1 Funding to …
Apr 10, 2022 Funding will support development of OSM-0205 through IND filing. New Haven, CT. April 12, 2022 – Osmol Therapeutics, a privately held biopharmaceutical company …See details»
In the Media - Osmol Therapeutics
CEO of Osmol Therapeutics Leads Virtual Charge to Develop Ground-Breaking Treatment for Prevent Chemo Side-Effects September 29, 2021 / 0 Comments / in In the Media / by malford. …See details»
Yale Spinout, Osmol, Gets Approval to Initiate First ... - Yale …
Sep 20, 2023 May Proceed Up to 80% of taxane treated breast cancer patients are diagnosed with some degree of CIPN Currently there are no FDA-approved treatments for CIPNOsmol …See details»
PR — OSMOL Therapeutics
Osmol Therapeutics Provides Corporate Update at BIOTECH SHOWCASE 2023. Osmol Therapeutics, today announced that it is presenting at BIOTECH SHOWCASE 2023, a leading …See details»
FDA Notifies Osmol Therapeutics that the First-in-Human Phase 1 ...
FDA Notifies Osmol Therapeutics that the First-in-Human Phase 1 Clinical Trial of OSM-0205 for the Prevention of Chemotherapy-induced Peripheral Neuropathy (CIPN) May ProceedSee details»
FDA Notifies Osmol Therapeutics that the First-in-Human Phase 1 ...
Sep 18, 2023 NEW HAVEN, Conn.--(BUSINESS WIRE)--Osmol Therapeutics, a privately held biopharmaceutical company focused on developing a treatment to prevent chemotherapy …See details»
5_15_24 — OSMOL Therapeutics
New Haven, CT – May 15, 2024 – Osmol Therapeutics, a privately held clinical-stage biopharmaceutical company focused on developing preventative treatments for chemotherapy …See details»
Osmol Therapeutics Announces Closing of Series A-1 ... - Business …
Apr 12, 2022 NEW HAVEN, Conn.--(BUSINESS WIRE)--Osmol Therapeutics, a privately held biopharmaceutical company focused on developing a treatment to prevent chemotherapy …See details»
Our Approach - OSMOL Therapeutics
Our Approach At Osmol Therapeutics, we are focused on advancing OSM-0205, a patented drug with a unique, first-in-class mechanism for modulating intracellular calcium, a known trigger for …See details»
News — OSMOL Therapeutics
9.29.21 - CEO of Osmol Therapeutics Leads Virtual Charge to Develop Ground-Breaking Treatment for Prevent Chemo Side-Effects Bob Linke, CEO of Osmol, was interviewed for the …See details»